---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009840"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:50:14.390737+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies reports preliminary Q4/FY2025 revenue growth of 51%/55% YoY

## Summary
- Total revenue FY2025 ~$277M (+55% YoY); Q4 ~$72M (+51% YoY).
- MRD revenue FY2025 ~$212M (+46% YoY); excluding milestone revenue grew 45%.
- clonoSEQ test volume FY2025 ~105,600 tests (+39% YoY); Q4 ~30,000 tests (+43% YoY).
- Cash, cash equivalents and marketable securities ~$227M as of Dec 31, 2025.
- Company expects full FY2025 net loss to decrease vs 2024; complete results due Feb 2026.

## SEC filing metadata
- accession: 0001193125-26-009840
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000119312526009840/0001193125-26-009840-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000119312526009840/d29941d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009840
- JSON: https://secwatch.observer/filing/0001193125-26-009840.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009840.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.